"Hurry up and wait" remains the order of the day for Neurocrine Biosciences (NASDAQ:NBIX).
This research-stage biotech has a big year on the way in 2015, with key
data expected on both Elagolix and the VMAT2 inhibitor NBI-98854 (or
'854). Strong efficacy and safety data could add $7 to $10 per share in
value, while disappointing results would certainly have a negative
impact on the shares. These shares still look undervalued today, though,
and the possibility of new clinical candidates and/or buyout rumors
could add a little excitement before year-end.
Read more here:
Neurocrine Biosciences Looking Forward To A Big Year
No comments:
Post a Comment